Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis

• Published in: Journal of Psychopharmacology 2023-02, Vol.37 (2), p.135-143
• Main Authors: Rafizadeh, Reza, Danilewitz, Marlon, Bousman, Chad A, Mathew, Nickie, White, Randall F, Bahji, Anees, Honer, William G, Schütz, Christian G
• Format: Article
• Language: English
• Subjects: Antipsychotic Agents - adverse effects; Antipsychotics; Clozapine; Clozapine - therapeutic use; Comorbidity; Drug use; Female; Hospitalization; Humans; Male; Mental disorders; Meta-analysis; Nicotine; Nicotine - therapeutic use; Observational Studies as Topic; Psychosis; Psychotropic drugs; Reviews; Schizophrenia; Schizophrenia - drug therapy; Substance use; Substance use disorder; Substance-Related Disorders - psychology; Systematic review
• ISSN: 0269-8811; 1461-7285
• DOI: 10.1177/02698811221142575

Background: Antipsychotic medications are the mainstay of treatment for schizophrenia and are associated with a reduction in psychiatric hospitalization and overall mortality. Some evidence suggest that antipsychotic medications might have a varying effect on the improvement of comorbid substance use disorders (SUDs), with clozapine showing more favorable outcomes. Aim: We systematically reviewed all available evidence on effects of clozapine on the improvement of SUDs other than nicotine. Methods: Electronic searches of MEDLINE, Embase, PsycINFO, and CINHAL were conducted up to March 1, 2022. Studies of any methodological design involving two concepts: (1) clozapine and (2) SUD terms (excluding nicotine) were included. For SUD outcomes with three or more comparative studies with available raw data meta-analysis was performed. SUD outcomes not meeting criteria for meta-analysis were described qualitatively. Risk of bias was examined using “Downs and Black,” and “Q-Coh” instruments. Results: The majority of individuals in the included 31 studies were male and of European ancestry. Abstinence was the most common outcome. Most of the studies were of low-to-moderate quality, and none of the studies met all the quality criteria. Pooled findings from four observational studies in samples of patients with predominantly comorbid alcohol use disorder showed that clozapine treatment is associated with significantly higher odds of remaining abstinent. In addition clozapine was associated with decreased odds of psychiatric hospitalization in all but one observational study. Conclusions: Our systematic review and meta-analysis builds upon previous reviews, and it suggests the association of clozapine treatment with significantly higher odds of remaining abstinent from substance use and decreased likelihood of psychiatric hospitalization, compared with continuing treatment with other antipsychotic medications. Still, the validity of this association needs greater exploration and providing recommendations for the utility of clozapine in individuals without treatment-resistant psychosis and comorbid SUDs would be premature.